{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T15:45:05Z","timestamp":1649087105527},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2010,8,8]],"date-time":"2010-08-08T00:00:00Z","timestamp":1281225600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Z. Rheumatol."],"published-print":{"date-parts":[[2010,9]]},"DOI":"10.1007\/s00393-009-0528-1","type":"journal-article","created":{"date-parts":[[2010,8,7]],"date-time":"2010-08-07T13:43:32Z","timestamp":1281188612000},"page":"594-600","source":"Crossref","is-referenced-by-count":2,"title":["Rituximab"],"prefix":"10.1007","volume":"69","author":[{"given":"E.","family":"Feist","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"D\u00f6rner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,8,8]]},"reference":[{"key":"528_CR1","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1002\/art.22817","volume":"56","author":"Bang","year":"2007","unstructured":"Bang H, Egerer K, Gauliard A et al (2007) Mutation and citrullination modifies vimentin to a novel autoantigen for rheumatoid arthritis. Arthritis Rheum 56:2503\u20132511","journal-title":"Arthritis Rheum"},{"key":"528_CR2","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.3899\/jrheum.091127","volume":"37","author":"Bastian","year":"2010","unstructured":"Bastian H, Zinke S, Egerer K et al (2010) Effects of early rituximab retreatment in rheumatoid arthritis patients with an inadequate response after the first cycle: retrospective arthritis cohort study. J Rheumatol 37:1069\u20131071","journal-title":"J Rheumatol"},{"key":"528_CR3","doi-asserted-by":"crossref","first-page":"iii64","DOI":"10.1136\/ard.2008.097972","volume":"67","author":"Calabrese","year":"2008","unstructured":"Calabrese LH, Molloy ES (2008) Progressive multifocal leucoencephalopathy in the rheumatic diseases: assessing the risks of biological immunosuppressive therapies. Ann Rheum Dis 67(Suppl 3):iii64\u2013iii65","journal-title":"Ann Rheum Dis"},{"key":"528_CR4","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/S1470-2045(09)70161-5","volume":"10","author":"Carson","year":"2009","unstructured":"Carson KR, Focosi D, Major EO et al (2009) Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a review from the Research on Adverse Drug Events and Reports (RADAR) project. Lancet Oncol 10:816\u2013824","journal-title":"Lancet Oncol"},{"key":"528_CR5","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1136\/ard.2008.089276","volume":"69","author":"Chatzidionysiou","year":"2010","unstructured":"Chatzidionysiou K, van Vollenhoven RF, Nasononov E et al (2010) [FRI0196] Efficacy of rituximab retreatment in clinical practice: data from the CERRERA Collaboration. Ann Rheum Dis 69 (Suppl3):380","journal-title":"Ann Rheum Dis"},{"key":"528_CR6","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1002\/art.22025","volume":"54","author":"Cohen","year":"2006","unstructured":"Cohen SB, Emery P, Greenwald MW et al (2006) Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 54:2793\u20132806","journal-title":"Arthritis Rheum"},{"key":"528_CR7","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1056\/NEJMoa032534","volume":"350","author":"Edwards","year":"2004","unstructured":"Edwards JC, Szczepanski L, Szechinski J et al (2004) Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 350:2572\u20132581","journal-title":"N Engl J Med"},{"key":"528_CR8","doi-asserted-by":"crossref","unstructured":"Emery P, Deodhar A, Rigby WF et al (2010) Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab\u2019s Efficacy in MTX iNadequate rEsponders (SERENE)). Ann Rheum Dis [Epub ahead of pring May 24]","DOI":"10.1136\/ard.2009.119933"},{"key":"528_CR9","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1002\/art.21778","volume":"54","author":"Emery","year":"2006","unstructured":"Emery P, Fleischmann R, Filipowicz-Sosnowska A et al (2006) The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 54:1390\u20131400","journal-title":"Arthritis Rheum"},{"key":"528_CR10","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1002\/art.22520","volume":"56","author":"Finckh","year":"2007","unstructured":"Finckh A, Ciurea A, Brulhart L et al (2007) B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents. Arthritis Rheum 56:1417\u20131423","journal-title":"Arthritis Rheum"},{"key":"528_CR11","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1136\/ard.2007.074773","volume":"67","author":"Genovese","year":"2008","unstructured":"Genovese MC, Schiff M, Luggen M et al (2008) Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy. Ann Rheum Dis 67:547\u2013554","journal-title":"Ann Rheum Dis"},{"key":"528_CR12","unstructured":"G\u00f3mez-Reino JJ, Sanmart\u00ed R, Romero AB et al (2010) [STAT0155] Switching to rituximab vs tnf-inhibitor cycling in patients with an inadequate response to tnf inhibitors: The MIRAR Study. Ann Rheum Dis"},{"key":"528_CR13","first-page":"194","volume":"67","author":"Gottenberg","year":"2008","unstructured":"Gottenberg J, Ravaud P, Bardin T et al (2008) [THU0181] Prospective follow-up of rituximab treatment in 804 patients with refractory rheumatoid arthritis (466 patients\/year): tolerance and safety data form the French Registry AIR (Autoimmunity and Rituximab). Ann Rheum Dis 67(Suppl 2):194","journal-title":"Ann Rheum Dis"},{"key":"528_CR14","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1136\/ard.2008.093781","volume":"68","author":"Isaacs","year":"2009","unstructured":"Isaacs JD, Olech E, Tak PP et al (2009) Autoantibody-positive rheumatoid arthritis (RA) patients (PTS) have enhanced clinical response to rituximab (RTX) When compared with seronegative patients. Ann Rheum Dis 68 (Suppl):442 [abstract]","journal-title":"Ann Rheum Dis"},{"key":"528_CR15","doi-asserted-by":"crossref","first-page":"3896","DOI":"10.1002\/art.23059","volume":"56","author":"Keystone","year":"2007","unstructured":"Keystone E, Fleischmann R, Emery P et al (2007) Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis. Arthritis Rheum 56:3896\u20133908","journal-title":"Arthritis Rheum"},{"key":"528_CR16","doi-asserted-by":"crossref","unstructured":"Gottenberg J, Ravaud P, Bardin T et al (2010) Risk factors of severe infections in patients with rheumatoid arthritis treated with rituximab in the AutoImmunity and Rituximab (AIR) registry. Arthritis Rheum [Epub ahead of print May 6]","DOI":"10.1002\/art.27555"},{"key":"528_CR17","first-page":"1687","volume":"60","author":"Mariette","year":"2009","unstructured":"Mariette X, Kivitz A, Isaacs JD et al (2009) Effectiveness of rituximab (RTX) + methotrexate (MTX) in patients (PTS) with early active rheumatoid arthritis (RA) and disease characteristics associated with poor outcomes. Arthritis Rheum 60 (Suppl):1687 [abstract]","journal-title":"Arthritis Rheum"},{"key":"528_CR18","doi-asserted-by":"crossref","unstructured":"Rubbert-Roth A, Tak PP, Zerbini C et al (2010) Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a phase III randomized study (MIRROR). Rheumatology (Oxford) [Epub ahead of pring May 12]","DOI":"10.1093\/rheumatology\/keq116"},{"key":"528_CR19","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/S0140-6736(09)60506-7","volume":"374","author":"Smolen","year":"2009","unstructured":"Smolen JS, Kay J, Doyle MK et al (2009) Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet 374(9685):210\u2013221","journal-title":"Lancet"},{"key":"528_CR20","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1136\/ard.2006.061002","volume":"66","author":"Smolen","year":"2007","unstructured":"Smolen JS, Keystone EC, Emery P et al (2007) Consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis 66:143\u2013150","journal-title":"Ann Rheum Dis"},{"key":"528_CR21","first-page":"338","volume":"66","author":"Tak","year":"2007","unstructured":"Tak PP, Cohen SB, Emery P et al (2007) Clinical response following the first treatment course with rituximab: effect of baseline autoantibody status (RF, anti-CCP). Ann Rheum Dis 66 (Suppl):338 [abstract]","journal-title":"Ann Rheum Dis"},{"key":"528_CR22","doi-asserted-by":"crossref","first-page":"3657","DOI":"10.1002\/art.24035","volume":"58","author":"Thurlings","year":"2008","unstructured":"Thurlings RM, Vos K, Gerlag DM, Tak PP (2008) Disease activity-guided rituximab therapy in rheumatoid arthritis: the effects of re-treatment in initial nonresponders versus initial responders. Arthritis Rheum 58:3657\u20133664","journal-title":"Arthritis Rheum"},{"key":"528_CR23","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1136\/ard.2007.076521","volume":"66","author":"Turesson","year":"2007","unstructured":"Turesson C, Eberhardt K, Jacobsson LT, Lindqvist E (2007) Incidence and predictors of severe extra-articular disease manifestations in an early rheumatoid arthritis inception cohort. Ann Rheum Dis 66:1543\u20131544","journal-title":"Ann Rheum Dis"},{"key":"528_CR24","doi-asserted-by":"crossref","first-page":"R12","DOI":"10.1186\/ar2362","volume":"10","author":"Ursum","year":"2008","unstructured":"Ursum J, Nielen MM, Schaardenburg D van et al (2008) Antibodies to mutated citrullinated vimentin and disease activity score in early arthritis: a cohort study. Arthritis Res Ther 10:R12","journal-title":"Arthritis Res Ther"},{"key":"528_CR25","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.autrev.2006.03.008","volume":"6","author":"Venrooij","year":"2006","unstructured":"Venrooij WJ van, Zendman AJ, Pruijn GJ (2006) Autoantibodies to citrullinated antigens in (early) rheumatoid arthritis. Autoimmun Rev 6:37\u201341","journal-title":"Autoimmun Rev"},{"key":"528_CR26","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1002\/art.27359","volume":"62","author":"Vital","year":"2010","unstructured":"Vital EM, Dass S, Rawstron AC et al (2010) Management of nonresponse to rituximab in rheumatoid arthritis: predictors and outcome of re-treatment. Arthritis Rheum 62:1273\u20131279","journal-title":"Arthritis Rheum"},{"key":"528_CR27","doi-asserted-by":"crossref","first-page":"558","DOI":"10.3899\/jrheum.090856","volume":"37","author":"Vollenhoven","year":"2010","unstructured":"Vollenhoven RF van, Emery P, Bingham CO 3rd (2010) Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials. J Rheumatol 37:558\u2013567","journal-title":"J Rheumatol"},{"key":"528_CR28","first-page":"68","volume":"69","author":"Gabay","year":"2010","unstructured":"Gabay C, Chatzidionysiou K, Nasonov E et al (2010) [OP0051] Effectiveness of different DMARD co-therapies in rituximab-treated rheumatoid arthritis (RA) patients \u2013 results of a one-year follow up study form the CERRERA Collaboration. Ann Rheum Dis 69 (Suppl 3):68","journal-title":"Ann Rheum Dis"},{"key":"528_CR29","first-page":"76","volume":"68","author":"Wendler","year":"2009","unstructured":"Wendler J, Soerensen H, Tony H et al (2009) [OP-0025] Effectiveness and safety of rituximab (RTX)-monotherapy compared to RTX-combination therapy with methotrexate (MTX) of leflunomide (LEF) in the German RTX Treatment of Active Rheumatoid Arthritis (RA) in Daily Practice Trial. Ann Rheum Dis 68 (Suppl 3):76","journal-title":"Ann Rheum Dis"},{"key":"528_CR30","first-page":"444","volume":"68","author":"Wendler","year":"2009","unstructured":"Wendler J, Soerensen H, Tony H et al (2009) [FRI0264] Continued treatment of rheumatoid arthritis (RA) with rituximab (RTX) in daily practice: 4. interim analysis of the German Prospective Multicenter Non-Interventional Study. Ann Rheum Dis 68 (Suppl 3):444","journal-title":"Ann Rheum Dis"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-009-0528-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00393-009-0528-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-009-0528-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T12:34:19Z","timestamp":1559392459000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00393-009-0528-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8,8]]},"references-count":30,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2010,9]]}},"alternative-id":["528"],"URL":"https:\/\/doi.org\/10.1007\/s00393-009-0528-1","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,8,8]]}}}